WP1066 for Brain Tumor

"WP1066's safety ranking, according to our team at Power, is a 1. This trial belongs in Phase 1 which indicates there is limited data on the drug's efficacy and safety profile."

"Affirmative. Data available on clinicaltrials.gov affirms that this medical study, initially posted in May of 2020, is recruiting patients now. Currently they are aiming to recruit 36 individuals from 1 site."

"Affirmative. Clinicaltrials.gov states that this medical trial, which was posted on May 4th 2020, is currently recruiting participants. 36 patients are required to be enrolled from a single location."

"The primary purpose of this investigation, which will be assessed over a period up to two months following the last dose of study medication, is determining the maximum tolerated dosage (MTD) of WP1066. Secondary objectives include assessing time-to-radiographically confirmed progression or response to treatment with WP1066 through imaging at baseline and 30 days later; examining pharmacokinetic parameters such as elimination half life (t1/2) and area under curve from zero to 24 hours after administration via both non-compartmental and compartmental methods."

"This trial is currently enrolling 36 patients aged 3 to 25 years old with a confirmed diagnosis of medulloblastoma. Aspiring participants must have completed any pre-existing medical treatments, including surgical interventions, radiation therapy and chemotherapy; in addition they must possess an overall performance rating on the Karnofsky or Lansky scale exceeding 60%. Furthermore, those suffering from DIPG or DMG H3K27M need not present histological confirmation when post-radiation but without signs of tumor progression."

"This trial has a specified age range of 3 to 25 years old. Additionally, there are 134 clinical trials targeting children under 18 and 365 for those aged 65 or above."